Cargando…

The prevalence and burden of Rome IV bowel disorders of gut brain interaction in patients with non-alcoholic fatty liver disease: a cross-sectional study

Rome IV bowel disorders of gut brain interaction (DGBI) and non-alcoholic fatty liver disease (NAFLD) are highly prevalent entities with overlapping pathophysiology and risk factors. We aimed to evaluate the prevalence and burden of Rome IV irritable bowel syndrome (IBS) in patients with NAFLD. Pati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Purssell, Huw, Bennett, Lucy, Street, Oliver, Hanley, Karen Piper, Hanley, Neil, Vasant, Dipesh H., Athwal, Varinder S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10229668/ https://www.ncbi.nlm.nih.gov/pubmed/37253969 http://dx.doi.org/10.1038/s41598-023-35774-5

Ejemplares similares

Non-alcoholic fatty liver disease in irritable bowel syndrome: More than a coincidence?
por: Purssell, Huw, et al.
Publicado: (2021)

Health Technology Adoption in Liver Disease: Innovative Use of Data Science Solutions for Early Disease Detection
por: Bennett, Lucy, et al.
Publicado: (2022)

Circadian Disruption Primes Myofibroblasts for Accelerated Activation as a Mechanism Underpinning Fibrotic Progression in Non-Alcoholic Fatty Liver Disease
por: Jokl, Elliot, et al.
Publicado: (2023)

Genetic Contribution to Non-alcoholic Fatty Liver Disease and Prognostic Implications
por: Martin, Katherine, et al.
Publicado: (2021)

Improving detection of cystic fibrosis related liver disease using liver fibrosis assessment tools()
por: Scott, Jennifer A., et al.
Publicado: (2023)

Direct healthcare costs of Rome IV or Rome III‐defined irritable bowel syndrome in the United Kingdom
por: Goodoory, Vivek C., et al.
Publicado: (2022)

Epimorphin Alters the Inhibitory Effects of SOX9 on Mmp13 in Activated Hepatic Stellate Cells
por: Pritchett, James, et al.
Publicado: (2014)

Prevalence, epidemiology and associated healthcare burden of Rome IV irritable bowel syndrome and functional dyspepsia in the adult population of Gibraltar
por: Kovács, Dénes Botond, et al.
Publicado: (2022)

What Is New in Rome IV
por: Schmulson, Max J, et al.
Publicado: (2017)

Impact of Rome IV irritable bowel syndrome on work and activities of daily living
por: Goodoory, Vivek C., et al.
Publicado: (2022)

Willingness to pay for medications among patients with Rome IV Irritable Bowel Syndrome
por: Goodoory, Vivek C., et al.
Publicado: (2022)

PAK proteins and YAP-1 signalling downstream of integrin beta-1 in myofibroblasts promote liver fibrosis
por: Martin, Katherine, et al.
Publicado: (2016)

Health care utilization of individuals with Rome IV irritable bowel syndrome in the general population
por: Tornkvist, Navkiran T., et al.
Publicado: (2021)

Functional Chronic Constipation: Rome III Criteria Versus Rome IV Criteria
por: Russo, Marina, et al.
Publicado: (2019)

The symptom burden of Irritable Bowel Syndrome in tertiary care during the COVID‐19 pandemic
por: Noble, Hithin, et al.
Publicado: (2022)

Functional gastrointestinal disorders in children: agreement between Rome III and Rome IV diagnoses
por: Baaleman, Desiree F., et al.
Publicado: (2021)

High prevalence of primary bile acid diarrhoea in patients with functional diarrhoea and irritable bowel syndrome-diarrhoea, based on Rome III and Rome IV criteria
por: Shiha, Mohamed G., et al.
Publicado: (2020)

Prevalence of Organic Colonic Lesions by Colonoscopy in Patients Fulfilling ROME IV Criteria of Irritable Bowel Syndrome
por: Paudel, Mukesh Sharma, et al.
Publicado: (2018)

Latent class analysis does not support the existence of Rome IV functional bowel disorders as discrete entities
por: Black, Christopher J., et al.
Publicado: (2022)

SOX9 regulated matrix proteins are increased in patients serum and correlate with severity of liver fibrosis
por: Athwal, Varinder S., et al.
Publicado: (2018)

Publisher Correction: SOX9 regulated matrix proteins are increased in patients serum and correlate with severity of liver fibrosis
por: Athwal, Varinder S., et al.
Publicado: (2019)

Burden of persistent symptoms in treated coeliac disease: cause, aftermath or merely association?
por: Vasant, Dipesh H
Publicado: (2022)

Understanding the Changes in Diagnostic Criteria for Functional Constipation in Pediatric Patients: From Rome III to Rome IV
por: Lee, Yoo Jin, et al.
Publicado: (2019)

Pros and Cons While Looking Through an Asian Window on the Rome IV Criteria for Irritable Bowel Syndrome: Pros
por: Ghoshal, Uday C
Publicado: (2017)

Predictive value of alarm symptoms in Rome IV irritable bowel syndrome: A multicenter cross-sectional study
por: Yang, Qian, et al.
Publicado: (2022)

Willingness to accept risk with medication in return for cure of symptoms among patients with Rome IV irritable bowel syndrome
por: Goodoory, Vivek C., et al.
Publicado: (2022)

Gut-focused hypnotherapy for children and adolescents with irritable bowel syndrome
por: Vasant, Dipesh H, et al.
Publicado: (2020)

The Differences in Prevalence and Sociodemographic Characteristics of Irritable Bowel Syndrome According to Rome II and Rome III
por: Park, Dong Won, et al.
Publicado: (2010)

Osteopontin Is a Novel Downstream Target of SOX9 With Diagnostic Implications for Progression of Liver Fibrosis in Humans
por: Pritchett, James, et al.
Publicado: (2012)

Prevalence of irritable bowel syndrome-like symptoms using Rome IV criteria in patients with inactive inflammatory bowel disease and relation with quality of life
por: Ozer, Muhammet, et al.
Publicado: (2020)

Irritable Bowel Syndrome Prevalence among Participants of Woodstock Rock Festival in Poland Based on Rome IV Criteria Questionnaire
por: Palma, Joanna, et al.
Publicado: (2021)

The Relevance of Food Constituents to the Irritable Bowel Syndrome: A Rome IV-Based Prevalence Study Among Medical Students
por: Mujamammi, Ahmed H., et al.
Publicado: (2023)

Is Rome III Criteria for Irritable Bowel Syndrome More Useful Than Rome II Criteria in Korea?
por: Park, Moo In
Publicado: (2010)

The Application of the Rome IV Criteria to Functional Esophagogastroduodenal Disorders in Asia
por: Suzuki, Hidekazu
Publicado: (2017)

Diagnosis and Management of Functional Chest Pain in the Rome IV Era
por: Fass, Ronnie, et al.
Publicado: (2019)

Classification of pediatric functional gastrointestinal disorders related to abdominal pain using Rome III vs. Rome IV criterions
por: Edwards, Trent, et al.
Publicado: (2018)

Functional gastrointestinal disorders in inflammatory bowel disease: Time for a paradigm shift?
por: Vasant, Dipesh H, et al.
Publicado: (2020)

Experience and clinical efficacy of gut‐directed hypnotherapy in an Asian population with refractory irritable bowel syndrome
por: Sasegbon, Ayodele, et al.
Publicado: (2022)

The prevalence of irritable bowel syndrome among Saudi population in Riyadh by use of Rome IV criteria and self-reported dietary restriction
por: Amin, Hussein S., et al.
Publicado: (2021)

The New Rome IV Criteria for Functional Gastrointestinal Disorders in Infants and Toddlers
por: Zeevenhooven, Judith, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_3i3lg0rgaudo74e39vqt8mtem1